These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 26984605

  • 1. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.
    J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN, Deeks ED.
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F, Volpe R, Pastorelli F, Bianchi A, Vella A, Rapezzi C, Mascalchi M.
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
    [Abstract] [Full Text] [Related]

  • 7. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.
    Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR.
    J Cardiovasc Transl Res; 2013 Dec; 6(6):1011-20. PubMed ID: 24101373
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
    Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Grogan DR.
    J Neurol; 2013 Nov; 260(11):2802-14. PubMed ID: 23974642
    [Abstract] [Full Text] [Related]

  • 10. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH.
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [Abstract] [Full Text] [Related]

  • 11. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ.
    Orphanet J Rare Dis; 2018 Dec 17; 13(1):225. PubMed ID: 30558645
    [Abstract] [Full Text] [Related]

  • 12. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
    Shintani Y, Okada A, Morita Y, Hamatani Y, Amano M, Takahama H, Amaki M, Hasegawa T, Ohta-Ogo K, Kanzaki H, Ishibashi-Ueda H, Yasuda S, Shimazaki C, Yoshinaga T, Yazaki M, Sekijima Y, Izumi C.
    ESC Heart Fail; 2019 Feb 17; 6(1):232-236. PubMed ID: 30478886
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR.
    Neurology; 2012 Aug 21; 79(8):785-92. PubMed ID: 22843282
    [Abstract] [Full Text] [Related]

  • 15. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
    Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D, French Network for FAP (CORNAMYL).
    Eur J Neurol; 2013 Dec 21; 20(12):1539-45. PubMed ID: 23834402
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
    Cárdenas-Soto K, Dominguez XH, Cortes G, Tsai F, Saniger MDM, Guraieb-Chahin P, Torres-Ocatvo B, Gibbons C, Kelly JW, Freeman R, González-Duarte A.
    J Peripher Nerv Syst; 2024 Jun 21; 29(2):221-231. PubMed ID: 38706223
    [Abstract] [Full Text] [Related]

  • 18. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y.
    J Neurol Neurosurg Psychiatry; 2015 Sep 21; 86(9):1036-43. PubMed ID: 25604431
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.
    Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J.
    J Cardiovasc Transl Res; 2015 Mar 21; 8(2):117-27. PubMed ID: 25743445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.